Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 1.00 |
| ▸ | CDK1 | P06493 | 7/20 | 0.53 |
| ▸ | IGF1R | P08069 | 7/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.53 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.53 |
| ▸ | JAK1 | P23458 | 7/20 | 0.53 |
| ▸ | CDK2 | P24941 | 7/20 | 0.53 |
| ▸ | AXL | P30530 | 7/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27817205 | 0.86 | SMO (0.75) | SMOCDK1IGF1RFGFR1BRAF | |
| SCHEMBL1830461 | 0.80 | SMO (1.00) | SMOCDK1IGF1RFGFR1BRAF | |
| SCHEMBL1832485 | 0.80 | SMO (1.00) | SMOCDK1IGF1RFGFR1BRAF | |
| SCHEMBL1829543 | 0.77 | SMO (0.65) | SMO | |
| SCHEMBL1828456 | 0.76 | SMO (1.00) | SMO | |
| SCHEMBL1842116 | 0.76 | SMO (0.68) | SMO | |
| SCHEMBL1828308 | 0.76 | SMO (0.61) | SMO | |
| SCHEMBL1831154 | 0.75 | SMO (0.60) | SMO | |
| SCHEMBL1830467 | 0.74 | SMO (0.70) | SMO | |
| SCHEMBL1830421 | 0.74 | SMO (0.59) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2318389-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | SMO 1/4885CDK1 46/4885IGF1R 261/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | SMO 1/4885CDK1 341/4885IGF1R 702/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | SMO 1/4885CDK1 341/4885IGF1R 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.